Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster.
Montserrat Torres, Magdalena Corona, Sara Rodríguez-Mora, Guiomar Casado-Fernández, Alejandro Zurdo-Castronuño, Elena Mateos, Fernando Ramos-Martín, Clara Sánchez-Menéndez, María Aranzazú Murciano-Antón, Javier García-Pérez and 6 more
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 4 institutions in 1 country.
Montserrat TorresImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
Magdalena CoronaHematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-6553-0171
Sara Rodríguez-MoraImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.ORCID 0000-0003-2467-116X
Guiomar Casado-FernándezImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
Alejandro Zurdo-CastronuñoHematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Elena MateosImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
Fernando Ramos-MartínImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
Clara Sánchez-MenéndezImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
María Aranzazú Murciano-AntónFamily Medicine, Centro de Salud Doctor Pedro Laín Entralgo, 28924 Alcorcón, Spain.
Javier García-PérezBiomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28220 Majadahonda, Spain.ORCID 0000-0001-7551-7803
José AlcamíBiomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28220 Majadahonda, Spain.ORCID 0000-0003-0023-7377
Mayte Pérez-OlmedaBiomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28220 Majadahonda, Spain.ORCID 0000-0003-4553-5423
Mayte CoirasImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.ORCID 0000-0001-6464-5770
Javier López-JiménezHematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Valentín García-GutiérrezHematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0003-4752-0815
On Behalf Of The Multidisciplinary Group Of Study Of Covid-Mgs-Covid
Instituto de Salud Carlos III · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESUniversidad de Alcalá · ESCentro de Salud Casa del Barco · ES
Funding
Tyrosine Kinase inhibition: The New Front in HIV Cure EffortsR01AI143567 · NIAID · UNIVERSITY OF UTAH · PI COIRAS, MAYTE, PLANELLES, VICENTE · 2019 to 2023
$2.3M
Chiesi Foundation DonationCoordinated Research Activities at the National Center of Microbiology (CNM, Instituto de Salud Carlos III) COV20_00679NIAID NIH HHS R01 AI143567NIH HHS R01AI143567Spanish Ministry of Science and Innovation PID2019-110275RB-I00Strategic Action in Health 2017-2020 of the Instituto de Salud Carlos III PI21/00877
6 · The paper itself
Abstract
The humoral immune response developed after receiving the full vaccination schedule against COVID-19 is impaired in individuals who received anti-CD20 therapy 6-9 months before vaccination. However, there is little information about the cellular immune responses elicited in these individuals. In this study, we analyzed the humoral and cellular immune responses in 18 individuals with hematological disease who received the last dose of rituximab 13.8 months (IQR 9.4-19) before the booster dose. One month after receiving the booster dose, the seroconversion rate in the rituximab-treated cohort increased from 83.3% to 88.9% and titers of specific IgGs against SARS-CoV-2 increased 1.53-fold (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster. · full record | OpenQuestion